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Abstract 
Objective(s)  
Four novel losartan analogues 5a-d were synthesized by connecting a dihydropyridine nucleus to imidazole 
ring. The effects of 5a and 5b on angiotensin receptors (AT1) and L-type calcium channels were investigated 
on isolated rat aorta.  
Materials and Methods 
Aortic rings were pre-contracted with 1 µM Angiotensin II or 80 mM KCl and relaxant effects of losartan, 
nifedipine, 5a and 5b were evaluated by cumulative addition of these drugs to the bath solution. 
Results 
The results showed that compounds 5a and 5b have both L-type calcium channel and AT1 receptor blocking 
activity. Their effects on AT1 receptors are 1000 and 100,000 times more than losartan respectively. The 
activity of compound 5b on L-type calcium channel is significantly less than nifedipine but compound 5a has 
comparable effect with nifedipine.  
Conclusion 
Finally we concluded that these two new Compounds can be potential candidates to be used as effective 
antihypertensive agents. 
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Introduction 
Angiotensin II (ANG II) is an important 
regulator of the renal microcirculation and 
exerts major actions on afferent and efferent 
arterioles (1-3). Although it has been clearly 
demonstrated that ANG II increases 
intracellular calcium ([Ca
2+]i) in vascular 
smooth muscle cells (RVSMC), the sequence 
of events following activation of ANG II type 
1 receptors (AT1) remains unclear (2, 4-6). 
Typically, the calcium response is 
characterized by a sharp transient rise in 
[Ca
2+]i followed by a fall toward a sustained 
plateau above baseline (2). Although the 
sustained increases in [Ca
2+]i are thought to be 
mediated through Ca
2+ influx, the early peak 
response is generally considered to be due to 
mobilization of intracellular stores (6-9). AT1 
receptor-coupled G proteins activate PLC, 
which, in turn, activates IP3 and DAG, leading 
to release of calcium from the sarcoplasmic 
reticulum (6, 10). It has been suggested that 
the increased [Ca
2+]i activates chloride 
channels (ClCa) causing an efflux of chloride 
and subsequent depolarization of the cell 
membrane leading to opening of voltage-gated 
calcium channels (11-16). L-type calcium 
channel blockers prevent constriction of 
afferent arterioles and reduce sustained [Ca
2+]i 
increases as well (5, 10, 16-18). 
Losartan (Dup-753) (Figure 1) is a nonpeptide 
angiotensin II receptor (type AT1) antagonist 
discovered by Duncia  et al in 1990 and its 
potassium salt (cozaar) has been marketed as an 
antihypertensive since 1995 (19).  
To date, many orally available sartans have 
been developed and are used in the treatment 
of both hypertension and damage associated 
with diseases like atherosclerosis and diabetes. 
In particular, the good properties of new non 
peptide ANG II antagonists, such as losartan, 
have stimulated the design of many different 
congeners. All these drugs contain some 
common structural features represented by a 
biphenyl fragment bearing an acidic moiety 
(i.e. tetrazole, carboxylic- or 
sulphonamidocarboxyl group), linked to a 
heteroaromatic or acyclic system by means of 
a methylene group. Almost all of the chemical 
manipulations within the fundamental skeleton 
of sartans, concerned the substitution of the 
imidazole ring of losartan with several 
variously substituted heteroaromatic groups or 
acyclic structures (20).  
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Figure 1. Losartan structure. 
 
In this project some novel analogues of 
losartan were synthesized in which biphenyl 
fragment was retained and imidazole nucleus 
was connected to a dihydropyridine moiety. 
We proposed dual calcium channel blocking 
and AT1 antagonist activity for the synthesized 
compounds. 
 
Materials and Methods 
Chemistry 
Melting points were determined on 
Electrothermal  Capillary  apparatus  and            
were uncorrected. The ir spectra were obtained 
using a Perkin-Elmer Model 1000. 1H nmr was 
obtained on Bruker Ac-80 spectrophotometer 
and chemical shifts (δ) were in ppm relative to 
internal tetramethylsilane. C, H, and N 
analyses were within ±0.4% of theoretical 
values. Title compounds (5a-d) are sensitive to 
light; all chemical procedures involving these 
were shielded from light whenever present. 
Compounds  1, 3a  and 3b were prepared as 
described previously (21). 
2-(n-butyl)-1-[(2’-(1-trityltetrazol-5-yl) 
biphenyl-4-yl) methyl] imidazole-4 -
carbaldehyde (3c)   and   2-(n-butyl)-1-[(2’-(1-
trityltetrazol-5-yl) biphenyl-4-yl) methyl] 
imidazole-5 –carbaldehyde (3d). 
A solution of 1 (1 g, 3.3 mmoles), potassium 
carbonate (1.8 g, 13.04 mmoles) and 2b (4.0 g, 
7.17  mmoles)  in  dried  dimethylformamide         
(25  ml)  was  stirred  at  room  temperature  for          
24 hr. The progress of reaction was controlled 
by thin layer chromatography on silica gel  
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(chloroform-methanol, 80:20). The reaction 
mixture was filtered, and the filtrate was 
concentrated under reduced pressure. The 
residue was diluted with water (20 ml) and 
extracted with chloroform (3×20 ml). The 
organic layer was collected and washed with 
brine, dried over anhydrous sodium sulfate, 
filtered and concentrated. A crude mixture of 
3c and 3d (1.44 g) was separated as pale 
yellow oil. This crude mixture was used 
directly at the next step. Also, preparative thin 
layer chromatography of this mixture on silica 
gel (chloroform-methanol, 80:20 as eluent) 
afforded respectively 64% of 3c and 36% of 
3d as pale yellow oils. 
Compound 3c has ir (sodium chloride disk): 
ν 1675 cm
-1 (C=O); 
1H-nmr 
(deuteriochloroform): δ 9.7 (s, 1H, CHO), 8.5-
6.5 (m, 24H, arom, HC4  imidazole),  4.5            
(s, 2H, CH2N), 2.5 (t, 3H, CH2),  2.0-0.5        
(m, 7H, CH2, CH3). 
Anal. Calcld. for C41H36N6O: C, 78.32 ; H, 
5.77; N,13.37 . 
Found:  C, 78.11; H, 5.68; N, 13.41.   
Compound 3d has ir (sodium chloride disk): 
ν 1675 cm
-1 (C=O); 1H-nmr 
(deuteriochloroform): δ 9.6 (s, 1H, CHO), 8.5-
6.5 (m, 9H, arom, HC5 imidazole), 5.5 (s, 2H, 
CH2N), 2.5 (t, 3H, CH2), 2.0-0.5 (m, 7H, CH2, 
CH3). 
Anal. Calcld. for C41H36N6O: C, 78.32; H, 
5.77; N,13.37. 
Found C, 78.22; H, 5.68; N, 13.45. 
 
Dimethyl 4-[2-butyl-1-(2’-carboxy biphenyl-4-
yl) methylimidazol-4-yl]-1, 4-dihydro-2, 6-
dimethylpyridine-3, 5-dicarboxylate (5a). 
Ammonium solution (1.1 ml) was added to a 
stirring solution of crude mixture 3a, b (1.25 g, 
3.32 mmol) and methyl acetoacetate (078 g, 
6.68 mmol) in methanol (25 ml). The mixture 
was protected from light and refluxed 
overnight. The solvent was evaporated under 
reduced pressure and the residue was purified 
by chromatography on silica gel (chloroform-
methanol, 70:30)  to  give 1.03 g (56%) of  5a 
as a white solid, mp 216 
oC (ethanol); ir 
(potassium bromide): ν 1687 cm
-1 (C=O);
 1H-
nmr (deuteriochloroform): 10.6 (s, 1H, 
COOH), 7.9-6.5 (m, 10H, arom, HC4 
imidazole, NH), 5.0 (m, 3H, HC4 
dihyropyridine, CH2N) 3.59 (s, 6H, CH3O), 
2.0 (s,  6H, CH3 dihydropyridine), 2.5 (m, 2H, 
CH2), 1.8 - 0.4 ppm (m, 7H, CH3, CH2).  
Anal. Calcld. for C32H35N3O6: C, 68.92; H, 
6.33 ; N,7.54. 
Found:  C, 68.84; H, 6.19; N, 7.67. 
 
Diethyl 4-[2-butyl-1-(2’-carboxy biphenyl-4-
yl) methylimidazol-4-yl]-1, 4-dihydro-2,6-
dimethylpyridine-3,5-dicarboxylate (5b). 
This compound was prepared in a similar 
fashion to 5a affording 5b as a white solid in 
57% yield; mp 189.5 (ethanol); ir (potassium 
bromide):  ν 1687 cm
-1  (C=O); 1H-nmr 
(deuteriochloroform): 10.8 (s, 1H, COOH), 
8.4-6.7 (m, 10H, arom, HC5 imidazole, NH), 
5.0 (m, 3H, HC4 dihyropyridine, CH2N)  3.9           
(q, 4H, CH2O), 2.0 (s, 6H, CH3 
dihydropyridine), 2.2 (m, 2H, CH2), 1.6 - 0.5 
ppm(m, 13H, CH3, CH2).  
Anal. Calcld. for C34H39N3O6: C, 69.72; H, 
6.71; N,7.17. 
Found:  C, 69.68; H, 6.84; N, 7.05. 
 
Dimethyl 4-[2-butyl-1-[2’-(1H-tetrazo-5-yl) 
biphenyl-4-yl] methylimidazol-4-yl]-1,4-
dihydro-2,6-dimethylpyridine-3,5-
dicarboxylate (5c). 
This compound was prepared in a similar 
fashion to 5a affording 5c as an yellow oil in 
30% yield; ir (sodium chloride): ν 1685cm
-1 
(C=O);
 1H-nmr (DMSO-d6):  8.8 (s, 1H, NH 
tetrazole), 8.0-6.4 (m, 10H, arom, HC5 
imidazole, NH), 4.8-4.7 (m, 3H, HC4 
dihyropyridine, CH2N), 3.35 (s, 6H, CH3O), 
2.3 (m, 2H, CH2), 2.0 (6H, CH3 
dihydropyridine), 1.7 - 0.5 ppm (m, 7H, CH3, 
CH2).  
Anal. Calcld. for C32H35N7O4: C, 66.08; H, 
6.06; N,16.86. 
Found: C, 66.17; H, 6.12; N, 16.95. 
 
Diethyl 4-[2-butyl-1-[2’-(1H-tetrazo-5-yl) 
biphenyl-4-yl] methylimidazol-4-yl]-1, 4-
dihydro-2,6-dimethylpyridine-3,5-
dicarboxylate (5d). 
This compound was prepared in a similar 
fashion to 5a affording 5d as a yellow oil in 
30%  yield; ir (sodium chloride): ν 1685 cm
-1  
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(C=O);
 1 H-nmr (DMSO-d6): 8.9 (s, 1H, NH 
tetrazole), 8.0-6.4 (m, 10H, arom, HC5 
imidazole, NH), 5.3-4.5 (m, 3H, HC4 
dihyropyridine, CH2N), 3.9 (q, 4H, CH2O), 2.5 
(t, 2H, CH2), 2.1 (6H, CH3 dihydropyridine), 
1.9 - 0.4 ppm (m, 13H, CH3, CH2).  
Anal. Calcld. for C34H39N7O4: C, 66.98; H, 
6.45 ; N,16.08. 
Found:  C, 66.87; H, 6.56; N, 16.19. 
 
Pharmacology 
ANG II, Nifedipine, Losartan and KCl were 
supplied by Sigma. ANG II and KCl were 
dissolved in distilled water. Nifedipine, 
losartan and compounds 5a and 5b were 
dissolved in dimethylsulphoxide (DMSO). 
DMSO in organ baths did not affect smooth 
muscle relaxations induced by compounds. All 
drug solutions were prepared on a daily basis. 
Male Wistar rats weighing 200–250 g were 
used. Animals were anesthetized with 
interaperitoneal injection of sodium thiopental 
(80 mg/kg) and their thoracic aorta was 
removed, cleaned of adhering fat and cut into 
rings of 3-4 mm long. All rings were mounted 
on stainless steel hooks in 20 ml organ baths. 
These organ chambers were filled with Krebs- 
Henseleit solution (KHS), with a composition 
(in mM) of: NaCl 118, KCl 4.7, MgSO4 2H2O 
1.2 KH2PO4, 2 H2O 1.2, NaHCO3 25, CaCl2 
2.5 and glucose 11.1, aerated with a mixture  
of 95% O2/5% CO2 and kept at 37 °C. The pH 
of  the  saturated  solution  was  7.4.  Changes            
in tension were recorded with an isometric 
transducer and displayed on a Washington 
recorder. After mounting, the preparations 
were allowed to equilibrate for 1 hr. During 
this time the resting tension was adjusted to               
2 g and solution was renewed every 15 min. 
Aortic rings were pre-contracted with 1 µM 
ANG II or 80 mM KCl and concentration-
response curve for losartan, nifedipine and 
compounds 5a and 5b were obtained by 
cumulative addition of these drugs to the bath 
solution. The relaxant effects of the 
compounds were expressed as percentage of 
the pre-contraction. To evaluate the effects of 
the compounds, pD2 values (the negative 
logarithm of the concentration for the half-
maximal response (EC50)) were calculated. All 
data are expressed as mean±standard error. 
Statistical comparisons between groups were 
performed using unpaired t-test and P values 
of less than 0.05 were considered to be 
statistically significant. 
 
Results and Discussion 
Chemistry  
Compound 1 was synthesized as reported 
previously (21). Alkylation of 1 with 
bisphenylmethyl bromide 2a, b gave a 70:30 
mixture  of  isomeric  4(5)-formylimidazoles      
3a-d with 4 -isomers predominance. The 
proportion of isomers was determined by 
1H-
NMR. Benzylic protons of 5-isomer (3b, d) 
were more deshielded than that of 4-isomer 
(3a, c) which appeared at 5.63 and 5.17 
respectively (scheme 1).  
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N
H n-Bu
CHO
R
Br N
N n-Bu
CHO
R
4
5
2a) R = COOMe
1
+
3a) 4-CHO, R= COOMe
3b) 5-CHO, R=COOMe N
N
N
N
CPh3
2b) R=
3c) 4-CHO, R =
N
N
N
N
CPh3
3d) 5-CHO, R =
N
N
N
N
CPh3
Scheme 1. Synthesis of compounds 3a-d. 
 
The cured isomeric mixture was reacted with 
acetoacetate 4a, b and ammonia in methanol 
according to classical Hanzsch condensation to 
afford dihydropyridines 5a-d (scheme 2). 
Mostly, the predominant 4 isomer 3a, c was 
condensed. This may be related to steric 
hinderance of 5 isomer dihydropyridines if 
formed.  It was interesting that trityl protecting 
groups were removed in situ during reaction in 
ammonia solution. Usually trityl protecting 
group is removed at acidic media (22). Ester 
groups on 2’ position of bisphenyl (R) were 
also hydrolyzed while dihydropyridine esters 
(R’) remained intact. Carbonyl group of ester 
at 2’ position is co-planar with phenyl ring and 
consequently is more prone to hydrolysis than  
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carbonyl group of esters at 3 and 5 position of 
dihydropyridine nucleus. 
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Scheme 2. . Synthesis of compounds 5a-d. 
 
Pharmacology 
The relaxant effect of the test compounds 5a 
and 5b, nifedipine and losartan on isolated 
rings of rat aorta precontracted by potassium 
chloride (KCl) or angiotensin II (ANG II) 
were  given  in  Tables  1  and  2.  The  results           
of  the  first  part  of  the  study  indicate             
that  compounds  5a  and  5b  both  caused          
dilation against potassium chloride-induced 
contraction. The activity of compound 5b is 
significantly lower than nifedipine (P<0.05) 
but  compound  5a  has  comparable  effect       
with nifedipine. Losartan also causes dilation 
against potassium chloride-induced 
contraction which was significantly lower than 
nifedipine (P<0.05). Altogether, compounds 
5a and 5b, nifedipine and losartan exerted 
concentration-dependent relaxation responses 
on aortic rings precontracted by KCl with 
potency order of: nifedipine ≥ 5a > losartan> 5b. 
  Regarding  the  mechanism  of  contraction 
induced by KCl,  which activates L-type 
calcium channels of smooth muscles (23), our 
data indicates that the blocking effect of 
compound 5b on L-type calcium channels is 
less than nifedipine but for compound 5a is 
comparable with nifedipine. Our data also 
show  that  losartan  has  blocking  effect  on        
L-type calcium channels with lower potency 
compared to nifedipine. This finding is in 
accordance with the results of the work of 
Louch  et al which showed that losartan by 
itself  reduces incidence of transient inward 
current in ventricular myocytes (24). 
 To investigate the effect of compounds on 
Angiotensin receptor 1 (AT1), aortic rings 
were contracted by ANG II and then the 
relaxant effects of compounds were measured. 
The results showed that both compounds 5a 
and 5b cause dilation against ANG II-induced 
contraction. The activity of compounds 5a and 
5b is significantly higher than losartan 
(P<0.05) as positive control. The EC50  of 
compound 5b and 5a are 100,000 and 1000 
times more than losartan respectively. 
Comparing two compounds with each other 
we can say that compound 5b has higher 
potency than compound 5a on AT1 receptor 
while we showed that on L-type calcium 
channels, the potency of compound 5a was 
higher than compound 5b.  Our data show that 
nifedipine also has relaxant effect on ANG II-
induced contraction in isolated aorta but its 
effect is significantly lower than losartan 
(P<0.05). Although nifedipine doesn’t have 
antagonistic activity on AT1 receptors, it 
should be considered that a part of contraction 
induced by ANG II is due to activation of L-
type calcium channels. Therefore nifedipine 
can diminish contraction on ANG II but with a 
lesser potency than losartan. In another study it 
has been shown that a part of the ANG II-
induced constriction of renal resistance vessels 
is mediated by voltage-dependent L-type 
calcium channels responsive to the 
dihydropyridine nifedipine (16). 
    Regarding these data, we should consider 
that for compounds 5a and 5b and also for 
losartan, relaxant effect on ANG II contracted 
aorta is due to both AT1 receptor antagonism 
and calcium channel blocking activity.  
Table 1. Relaxant effects of nifedipine, losartan and compounds 5b and 5a on KCl-induced contraction  
Statistics 
(Comparison whit nifedipine)  pD2  Contractile stimulus  Compound 
*  -4.29±0.72  KCl  5b 
n.s.  -5.29±0.16  KCl  5a 
*  -4.58±0.1  KCl  Losartan 
_  -5.58±0.19  KCl  Nifedipine 
Relaxation is expressed as pD2 of precontraction induced by KCl (80 mM). pD2 values represent mean value±SE for 6 
experiments. ns, P> 0.05; *, P< 0.05 when compared with control (nifedipine). (unpaired t-test).   
Farzin  Hadizadeh et al 
          Iran J Basic Med Sci, Vol. 13, No.1, Winter 2010    200 
 
Table 2.  Relaxant effects of nifedipine, losartan and compounds 5a and 5b on angiotensin-induced contraction. 
Statistics 
(Comparison with losartan)  pD2  Contractile stimulus  Compound 
*  -8.67±0.18  Angiotensin II  5a 
*  -10.52±0.18  Angiotensin II  5b 
*  -4.50±0.1  Angiotensin II  Nifedipine 
_  -5.66±0.16  Angiotensin II  Losartan 
Relaxation is expressed as pD2 of precontraction induced by Angiotensin II (1 µM). pD2 values represent mean 
value±SE for 6 muscle rings ; *, P< 0.05 when compared with control (losartan). (unpaired t-test).  
 
 
Anyway, in comparison AT1 receptor 
antagonistic activity of these compounds, we 
can at least say that compound 5b is more 
potent than losartan, because as we mentioned 
above the relaxant effect of compound 5b on 
ANG II contracted aorta is 100,000 times more 
than losartan; while compound 5b and losartan 
are semi potent on L-type calcium channels. 
It can be concluded from these data that 
compounds 5b and 5a have both calcium 
channel and AT1 receptor blocking activity.  
Their effects on AT1 receptors are 100,000 
and 1000 times more than losartan 
respectively. Finally we can conclude that 
these two new compounds can be potential 
candidates to be used as effective 
antihypertensive agents. 
 
Acknowledgment 
The authors are thankful to the financial 
support of the Research Council of Mashhad 
University of Medical Sciences. The authors 
declare that they have no conflict of interests. 
 
References 
1. Arendshorst WJ, Brannstrom K, Ruan X. Actions of angiotensin II on the renal microvasculature. J Am Soc 
Nephrol 1999; 10:S149-S61. 
2. Inscho EW, Mason MJ, Schroeder AC, Deichmann PC, Stiegler KD, Imig JD. Agonist-induced calcium 
regulation in freshly isolated renal microvascular smooth muscle cells. J Am Soc Nephrol 1997; 8:569-579. 
3. Iversen BM, Arendshorst WJ.ANG II and vasopressin stimulate calcium entry in dispersed smooth muscle cells 
of preglomerular arterioles. Am J Physiol Renal Physiol 1998; 274:F498-F508. 
4. Conger JD, Falk SA, Robinette JB. Angiotensin II-induced changes in smooth muscle calcium in rat renal 
arterioles. J Am Soc Nephrol 1993; 3:1792-1803. 
5. Ruan X, Arendshorst WJ. Calcium entry and mobilization signaling pathways in ANG II-induced renal 
vasoconstriction in vivo. Am J Physiol 1996; 270:F398-405. 
6. Salomonsson M, Sorensen CM, Arendshorst WJ, Steendahl J, Holstein-Rathlou NH. Calcium handling in 
afferent arterioles. Acta Physiol Scand 2004; 181:421-429. 
7. Iversen BM, Arendshorst WJ. ANG II and vasopressin stimulate calcium entry in dispersed smooth muscle cells 
of preglomerular arterioles. Am J Physiol 1998; 274:F498-508. 
8. Iversen BM, Arendshorst WJ. AT1 calcium signaling in renal vascular smooth muscle cells. J Am Soc Nephrol 
1999; 10:11:584-589. 
9. Loutzenhiser K, Loutzenhiser R. Angiotensin II-induced Ca (2+) influx in renal afferent and efferent arterioles: 
differing roles of voltage-gated and store-operated Ca (2+) entry. Circ Res 2000; 87:551-557. 
10. Navar LG, Inscho EW, Majid SA, Imig JD, Harrison-Bernard LM, Mitchell KD. Paracrine regulation of the 
renal microcirculation. Physiol Rev 1996; 76:425-536. 
11. Carmines PK. Segment-specific effect of chloride channel blockade on rat renal arteriolar contractile responses 
to angiotensin II. Am J Hypertens 1995; 8:90-94. 
12. Jensen BL, Skott O. Blockade of chloride channels by DIDS stimulates renin release and inhibits contraction of 
afferent arterioles. Am J Physiol 1996; 270:F718-727. 
13. Large WA, Wang Q. Characteristics and physiological role of the Ca (2+)-activated Cl- conductance in smooth 
muscle. Am J Physiol 1996; 271:C435-454. 
14. Steendahl J, Holstein-Rathlou NH, Sorensen CM, Salomonsson M. Effects of chloride channel blockers on rat 
renal vascular responses to angiotensin II and norepinephrine. Am J Physiol Renal Physiol 2004; 286:F323-330. 
15. Takenaka T, Kanno Y, Kitamura Y, Hayashi K, Suzuki H, Saruta T. Role of chloride channels in afferent 
arteriolar constriction. Kidney Int 1996; 50:864-872. 
16. Ruan X, Arendshorst WJ. Calcium entry and mobilization signaling pathways in ANG II-induced renal 
vasoconstriction in vivo. Am J Physiol 1996; 270:F398-F405.  
Dihydropyridines as Angiotensin Antagonist 
 
 Iran J Basic Med Sci, Vol. 13, No.1, Winter 2010      201
17. Carmines PK, Navar LG. Disparate effects of Ca channel blockade on afferent and efferent arteriolar responses 
to ANG II. Am J Physiol 1989; 256: F1015-1020. 
18. Takenaka T, Suzuki H, Okada H, Inoue T, Kanno Y, Ozawa Y, et al. Transient receptor potential channels in 
rat renal microcirculation: actions of angiotensin II. Kidney Int 2002; 62:558-565. 
19. Wang JW, Jia J, Li HM, Wang C. Synthesis of Novel Isoxazole-contained Analogues of Losartan. Chin Chem 
Lett 2000; 11:961-962. 
20. Rapposelli S, Cuboni S, Digiacomo M, Lapucci A, Trincavelli ML, Tuccinardi T, et al. Synthesis and AT1 
affinity evaluation of benzamidophenyl analogs of known AT1 receptor ligands with similar aromatic skeleton. 
Arkivoc 2008; 2008:268-286. 
21. Shafiee A, Shahbazi-Mojarad J, Jalili MA, Adhami HR, Hadizadeh F. Syntheses of substituted pyrrolo[2,3-
d]imidazole-5-carboxylates and substituted pyrrolo[3,2-d]imidazole-5-carboxylates. J Heterocycl Chem 2002; 
39:367-373. 
22. Guo XZ, Shi L, Wang R, Liu XX, Li BG, Lu XX. Synthesis and biological activities of novel nonpeptide 
angiotensin II receptor antagonists based on benzimidazole derivatives bearing a heterocyclic ring. Bioorg Med 
Chem 2008; 16:10301-10310. 
23. Drummond RM, Wadsworth RM. In vitro effect of nifedipine on KCl and 5-hydroxytryptamine-induced 
contractions of the sheep coronary, cerebral and pulmonary arteries. Life Sci 1994; 54:1081-1090. 
24. Louch WE, Ferrier GR, Howlett SE. Losartan improves recovery of contraction and inhibits transient inward 
current in a cellular model of cardiac ischemia and reperfusion. J Pharmacol Exp Ther 2000; 295:697-704. 
 